Dong-A ST confirmed the preventive effect of diabetic cardiomyopathy Suganon (Evogliptin), a new drug for the treatment of diabetes from the DPP-4 inhibitor class, published in the international journal ‘Experimental & Molecular Medicine’ published on the 25th.
This study was conducted by a joint research team including Professor Won Jong-cheol from the Department of Endocrinology of Sanggye Paik Hospital, Inje University, and Professor Kim Hyung-gyu from the Center for Cardiovascular and Metabolic Diseases, Inje University.
The research team administered evogliptin (100mg/kg/day) orally every day for 12 weeks to diabetic and obese model mice and observed the effect on diabetic cardiomyopathy, and found abnormal systolic and diastolic function of the heart in diabetic cardiomyopathy, confirmed a cardioprotective effect the heart evogliptin in the treatment of hypertrophy and fibrosis.
Diabetic cardiomyopathy is characterized by cardiac structural and functional abnormalities that occur in diabetic patients without coronary artery disease, uncontrolled hypertension, valvular heart disease and congenital heart disease. Although there is no clear cause and treatment, it is recently known that oxidative stress, fibrosis, and mitochondrial dysfunction in cardiomyocytes caused by abnormalities in fatty acid metabolism and lipid signaling system are the causes of obesity and diabetic patients.
In the study, evogliptin prevented cardiac lipotoxicity by reducing the accumulation of lipid droplets in the myocardium by inhibiting CD36, ACSL1, FABP3, PPARgamma, and DGAT1 and promoting the phosphorylation of FOXO1. It was confirmed that evogliptin mainly affects the genes involved ( DEGs).
It has also been shown to improve mitochondrial function and reduce damage by activating PGC1/NRF1/TFAM, which activates mitochondria.
Based on the results of the study, the research team suggested that evogliptin could be a potential treatment option for diabetic cardiomyopathy by improving heart function by reducing lipotoxicity and mitochondrial damage.
“Further research is needed, but this study proves that DPP-4 inhibition by evogliptin prevents diabetic cardiomyopathy by reducing cardiac lipotoxicity, mitochondrial damage and fibrosis in diabetic and obese mice,” said Professor Won Jong-cheol of the Department of Endocrinology at Sanggye Paik “It is meaningful that this is the first study,” he said. “It was confirmed that preventing the use of fatty acid through inhibition of DPP-4 is a promising strategy to improve cardiac efficiency in diabetic cardiomyopathy.”
Dong-A ST official said, “The research results of the joint research team at Sanggye Paik Hospital confirmed the possibility of Suganon to prevent diabetic cardiomyopathy.” “he said.
Meanwhile, Suganon is the 26th new Korean drug developed by Dong-A ST It has high selectivity for the DPP-4 enzyme, so it shows an excellent blood sugar lowering effect even with a small dose, and not has little effect on the metabolism of others. It is characterized by high drug taking convenience and disease patient compliance.
In particular, it has the advantage that it can be used without dose adjustment even in patients with reduced renal function.
.jpg?fit=300%2C300&ssl=1)
